1. Home
  2. XPER vs CTNM Comparison

XPER vs CTNM Comparison

Compare XPER & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xperi Inc.

XPER

Xperi Inc.

HOLD

Current Price

$6.11

Market Cap

278.9M

Sector

Technology

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$11.57

Market Cap

328.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPER
CTNM
Founded
1990
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
278.9M
328.1M
IPO Year
2003
2024

Fundamental Metrics

Financial Performance
Metric
XPER
CTNM
Price
$6.11
$11.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$11.00
$20.00
AVG Volume (30 Days)
467.0K
254.5K
Earning Date
11-05-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$453,960,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.26
N/A
P/E Ratio
$40.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.40
$3.35
52 Week High
$11.08
$15.25

Technical Indicators

Market Signals
Indicator
XPER
CTNM
Relative Strength Index (RSI) 49.60 51.22
Support Level $6.10 $11.50
Resistance Level $6.27 $13.48
Average True Range (ATR) 0.17 0.70
MACD 0.06 0.08
Stochastic Oscillator 68.66 41.98

Price Performance

Historical Comparison
XPER
CTNM

About XPER Xperi Inc.

Xperi Inc is a consumer and entertainment technology company. Its offering comprises a portfolio of software and services. The company creates extraordinary experiences at home and on the go for millions of consumers around the world, enabling audiences to connect with content in a more intelligent, immersive, and personal way. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment. Its also have sales in Japan, Europe and Middle East, China, South Korea, Latin America, and Others.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: